ICU Medical, Inc. (NASDAQ:ICUI) Stock Has Consensus Target Price of $192.80 According to Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, four have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $192.80.

A number of brokerages have weighed in on ICUI. Zacks Research downgraded ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. KeyCorp upped their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Needham & Company LLC raised their price objective on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings raised ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday.

ICU Medical Stock Performance

Shares of ICUI opened at $160.32 on Monday. The firm has a 50-day moving average of $168.41 and a 200-day moving average of $148.38. ICU Medical has a one year low of $112.50 and a one year high of $192.85. The company has a market cap of $4.01 billion, a PE ratio of 135.86, a price-to-earnings-growth ratio of 2.02 and a beta of 0.86. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.46. The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. ICU Medical’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the business earned $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, equities analysts forecast that ICU Medical will post 7.22 earnings per share for the current year.

Insiders Place Their Bets

In other ICU Medical news, insider Ben Sousa sold 2,250 shares of ICU Medical stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the completion of the transaction, the insider directly owned 3,076 shares of the company’s stock, valued at $548,512.32. The trade was a 42.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Virginia Sanzone sold 4,856 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the completion of the transaction, the vice president owned 14,604 shares in the company, valued at approximately $2,463,548.76. This represents a 24.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,830 shares of company stock worth $3,905,003 in the last quarter. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Several large investors have recently modified their holdings of the stock. Reinhart Partners LLC. boosted its stake in ICU Medical by 2.3% in the 3rd quarter. Reinhart Partners LLC. now owns 322,095 shares of the medical instruments supplier’s stock valued at $51,699,000 after purchasing an additional 7,327 shares during the period. Versant Capital Management Inc increased its position in ICU Medical by 26.2% during the 3rd quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 65 shares during the period. Squarepoint Ops LLC bought a new position in ICU Medical during the 2nd quarter worth $3,744,000. Allworth Financial LP increased its position in ICU Medical by 155.1% during the 2nd quarter. Allworth Financial LP now owns 176 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 107 shares during the period. Finally, Arizona State Retirement System lifted its holdings in shares of ICU Medical by 1.7% during the second quarter. Arizona State Retirement System now owns 6,551 shares of the medical instruments supplier’s stock worth $960,000 after buying an additional 109 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and critical care. Its products support the delivery of medications, fluids, and nutrition while helping healthcare providers reduce the risk of complications associated with intravenous treatment.

The company’s product portfolio includes infusion pumps and related administration sets, needle-free connectors, vascular access devices, intravenous systems, and other products used in hospitals and alternate-care settings.